Ece Nur Degirmentepe

Ece Nur Degirmentepe

Auto-generated profile, based on publicly available information

Ece Nur Degirmentepe

Dermatology Clinic Private Practice Sakarya Turkey

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in Journal of Dermatological Science
Verified
Journal Article
Closed access
EKEmek Kocatürk
Emek Kocatürk
PCPelin Kuteyla Can
Pelin Kuteyla Can
PAPırıl Etikan Akbas
Pırıl Etikan Akbas
MCMehmet Copur
Mehmet Copur
EDEce Nur Degirmentepe
Ece Nur Degirmentepe
RSRalfi Singer
Ralfi Singer

22 November 2023 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
SOSinem Ornek Ozdemir
Sinem Ornek Ozdemir
PCP. Kuteyla Can
P. Kuteyla Can
EDE. N. Degirmentepe
E. N. Degirmentepe
KCK. Cure
K. Cure
RSR. Singer
R. Singer
EKEmek Kocatürk
Emek Kocatürk
Background: Chronic inducible urticaria (CIndU) is a subtype of chronic urticaria (CU) which require specific physical or non‐physical triggers to occur. They may be isolated or may coexist with chronic spontaneous urticaria (CSU). Despite their frequent appearance in dermatology clinics, there is scarce information on the distinguishing features among the most common subtypes of CIndU as well as isolated CIndU versus CSU plus CIndU.Objectives: To compare clinical and laboratory characteristics, and comorbid conditions among the most common CIndU types and isolated CIndU versus CSU plus CIndU.Methods: We retrospectively analysed CIndU patients and compared patients' demographic, clinical and laboratory characteristics across isolated CIndU, CSU plus CIndU, symptomatic dermographism (SD), cold urticaria (ColdU) and cholinergic urticaria (ChoU).Results: A total of 423 patients (~70% isolated CIndU, ~30% CSU plus CIndU, ~5% mixed CIndU subtypes) were included in the study. The most frequent CIndU subtypes were SD (68.6%; 290/423), ColdU (11.4%; 48/423) and ChoU (10.9%; 46/423). Isolated CIndU patients were younger than CSU plus CIndU (33.74 ± 12.72 vs. 37.06 ± 11.84, p = 0.010). Angioedema, emergency referrals, need for systemic steroids, comorbid systemic disorders were more frequent and baseline urticaria control test scores were lower in CSU plus CIndU patients (vs. CIndU, p < 0.001, p = 0.008, p < 0.001, p = 0.031, p = 0.036, respectively). Among CIndU subtypes, ChoU patients were younger (24.9 ± 12.2 vs. 34.47 ± 12.12 vs. 31.38 ± 14.95; p < 0.001) and had male predominance (p < 0.001) while SD patients had no angioedema (p < 0.001) and had higher frequency of increased total IgE levels (p = 0.006).Conclusions: Isolated CIndU and CSU plus CIndU seems to be different endotypes of CU where CSU plus CIndU presents a more severe and refractory course. There are distinctive features of each CIndU subtype. These suggest involvement of different pathomechanistic pathways in these subtypes that need to be clarified in future studies.

1 January 2019 in Annals of Dermatology
Verified
Journal Article
Open access
EDEce Nur Degirmentepe
Ece Nur Degirmentepe
KKKubra Kızıltac
Kubra Kızıltac
PEPırıl Etikan
Pırıl Etikan
RSRalfi Singer
Ralfi Singer
BMBachar Memet
Bachar Memet
EKEmek Kocatürk
Emek Kocatürk
Degirmentepe EN, et al. Ann Dermatol. 2019 Jun;31(3):335-338. https://doi.org/10.5021/ad.2019.31.3.335

13 October 2021
Verified
Preprint
Open access
EKEmek Kocatürk
Emek Kocatürk
STSimon Francis Thomsen
Simon Francis Thomsen
MAMona Al-Ahmad
Mona Al-Ahmad
AGAna M. M Giménez-Arnau
Ana M. M Giménez-Arnau
NCNiall Conlon
Niall Conlon
MMMarcus Maurer
Marcus Maurer
Low and high IgE is linked to improvement and worsening of chronic urticaria during pregnancy, respectively Kocatürk E, Thomsen SF, Al-Ahmad M, Gimenez-Arnau A, Conlon N, Savk E, Criado RF, Danilycheva I, Fomina D, Khoshkhui M, Gelincik A, Degirmentepe EN, Demir S, Ensina LF, Kasperska-Zajac A, Rudenko M, Bauer A, Medina I, Maurer M.1 Urticaria Center of Reference and Excellence (UCARE), Dept. of Dermatology, Koç University School of Medicine, Istanbul, Turkey ekocaturk@ku.edu.tr2 Urticaria Center of Reference and Excellence (UCARE), Center of Reference and Excellence (UCARE), Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark simonfrancisthomsen@gmail.com3 Urticaria Center of Reference and Excellence (UCARE), Microbiology Department, Faculty of Medicine, Kuwait University, Safat, Kuwait monaalahmad@yahoo.com4 Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, Hospital del Mar, IMIM, Universitat Autònoma, Barcelona, Spain anamariagimenezarnau@gmail.com5 Urticaria Center of Reference and Excellence (UCARE), Dermatology, and Immunology, St James’s Hospital, Dublin, Ireland conlonn1@tcd.ie6 Aydın Adnan Menderes University, Aydın, Turkey esavk@adu.edu.tr7 Urticaria Center of Reference and Excellence (UCARE), Faculdade de Medicina do ABC (FMABC), Santo André, Brazil roberta.criado@fmabc.br8 Urticaria Center of Reference and Excellence (UCARE), NRC Institute of Immunology FMBA of Russia, Moscow, Russia ivdanilycheva@mail.ru9 Urticaria Center of Reference and Excellence (UCARE), First Moscow State Medical University, Moscow Center of Allergy and Immunology , Clinical Hospital 52 , Ministry of Moscow Healthcare, Moscow, Russia daria.s.fomina@gmail.com10 Urticaria Center of Reference and Excellence (UCARE), Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran Khoshkhuim@mums.ac.ir11 Urticaria Center of Reference and Excellence (UCARE), Istanbul Faculty of Medicine Istanbul University, Istanbul, Turkey gelincikasli@hotmail.com12 Urticaria Center of Reference and Excellence (UCARE), Okmeydani Training and Research Hospital, Istanbul, Turkey ecenuryksel@gmail.com13 Urticaria Center of Reference and Excellence (UCARE), Istanbul Faculty of Medicine Istanbul University, Istanbul, Turkey ERTANSEMRA@yahoo.com14 Urticaria Center of Reference and Excellence (UCARE), Federal University of São Paulo, Sao Paulo, Brazil 100alergia@gmail.com15 Urticaria Center of Reference and Excellence (UCARE), European Center for Diagnosis and Treatment of Urticaria (GA2LEN UCARE Network) Medical University of Silesia in Katowice, Poland alakasperska@gmail.com16 Urticaria Center of Reference and Excellence (UCARE), The London Allergy & Immunology Centre, London, United Kingdom consultation@ukallergy.com17 Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, University Allergy Center, University Hospital Carl Gustav Carus, Technical University Dresden, Germany. Andrea.Bauer@uniklinikum-dresden.de18 Urticaria Center of Reference and Excellence (UCARE), the Centro Médico Vitae, Buenos Aires, Argentina irisvmedina@gmail.com19 Urticaria Center of Reference and Excellence (UCARE), Dermatological Allergology, Allergie-Centrum-Charité, Dept. of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Germany marcus.maurer@charite.deDear Editor,PREG-CU, the recent study on pregnancy and chronic urticaria (CU) by the Urticaria Centers of Reference and Excellence (UCAREs), showed that CU improves in half (51.1%) of patients during pregnancy, whereas 28.9% and 20% of patients, respectively, experienced worsening and no change. Low disease activity, no angioedema, and no treatment before pregnancy were risk factors for worsening during pregnancy (1).We hypothesized that patients with chronic spontaneous urticaria (CSU) that worsens during pregnancy are more likely to have type I autoimmune CSU, also called autoallergic CSU. We also hypothesized that patients who improve during pregnancy are more likely to have type IIb autoimmune CSU (2). This hypothesis is supported by the immunological changes observed during pregnancy, i.e., decreased Th1 and Th17 immunity and a switch to a Th2-type cytokine profile (3).To test this hypothesis, we retrieved total IgE levels of CSU patients who gave consent to be included in the PREG-CU study (1). Elevated IgE levels have been reported to be linked to autoallergic CSU, whereas low IgE is a marker of type IIb autoimmune CSU (4).Total IgE blood levels were available for 115 of the 218 CSU patients not treated with omalizumab enrolled in PREG-CU. The median IgE level was 106 (range: 3-1664 IU/mL), more than half of patients (51.3%) had elevated IgE (≥100 IU/mL), and 17.4% had low IgE (<40 IU/mL). Most patients with mild disease (51%) or moderate disease (61%), but only one in four patients with severe disease (26%) had elevated IgE levels (≥100 IU/mL). IgE levels were lower in patients with severe disease (68 IU/mL) vs mild (112 IU/mL; p=0.009) or moderate disease (128 IU/mL; p=0.018), and low IgE levels (<40 IU/mL) were more frequent in patients with severe than mild disease (36.8 vs 11.6%; p=0.034).CSU patients who got worse during pregnancy had higher IgE levels (154 vs. 82.2 IU/mL; p=0.033) and numerically higher rates of elevated IgE (57.5 vs. 46%) compared to patients who got better during pregnancy. In contrast, patients who improved during pregnancy more often had low IgE levels than patients who deteriorated (22 vs. 12.5%), but this was not statistically significant. One in three of our patients (34.9%) had elevated anti-TPO, another marker of type IIb autoimmune CSU, but this was not linked to improvement during pregnancy.Worsening of CSU during pregnancy in patients with high IgE levels may be explained, in part, by the role that IgE and Th2 immunity play in the pathogenesis of their CSU. High IgE,...

1 January 2017 in Turkiye Klinikleri Journal of Dermatology
Verified
Journal Article
Open access
PDF file
EYEce Nur Yüksel
Ece Nur Yüksel
EKEmek Kocatürk
Emek Kocatürk
HDHatice Duman
Hatice Duman
AKAyşe Seza KUNTER
Ayşe Seza KUNTER
KCKübra Cüre
Kübra Cüre
ÖKÖzlem Korkmaz
Özlem Korkmaz
Becker nevüs veya diğer adıyla pigmente kıllı epidermal nevüs, sıklıkla üst ekstremitede ve gövdede yerleşen, hipertrikozisin eşlik ettiği unilateral, düzensiz hiperpigmente yamalar ile seyreden kutanöz bir hamartomdur. Hastaların büyük çoğunluğunda lezyonlar geç çocukluk ve adolesan dönemde başlamakta ve erkeklerde kadınlara göre 6 kat daha fazla görülmektedir. Becker nevüsün etiyolojisi tam olarak bilinmemekle birlikte, Becker nevüs ve androjen metabolizması arasında ilişki olduğu düşünülmektedir. Alt ekstremite, yüz gibi atipik lokalizasyonlu hastalar nadiren bildirilmiştir. Bu çalışmada, sol yanakta lokalize, asimetrik kıllanmanın eşlik ettiği, yüzde Becker nevüs tanısı koyduğumuz bir olgu sunulmuştur. Yüzde görülen ve üzerinde tüylenme izlenen hiperpigmentasyonda Becker nevüs de ayırıcı tanıda akla gelmelidir.

1 January 2016 in The Medical Journal of Okmeydani Training and Research Hospital
Verified
Journal Article
Closed access
EDEce Nur Değirmentepe
Ece Nur Değirmentepe